Filing Flows › Niagen Bioscience (NAGE) › Q2 2026 › vs Q2 2025
Niagen Bioscience (NAGE) Q2 2026 vs Q2 2025 (year over year)
Niagen Bioscience's revenue fell $1.3M (-4%) from $31.1M in Q2 2025 to $29.8M in Q2 2026. The biggest changes: Ingredients segment −$2.2M (-29%); Consumer Products segment +$1.5M (+6%). Gross margin 64.8% against 65.0% (-0.2 pts).
Niagen Bioscience, Q2 2026: revenue $29.8M (-4% year over year), operating margin 2.4%, net earnings $963K, operating cash flow $2.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 64.8% | 65.0% | -0.2 pts |
| Operating margin | 2.4% | 10.2% | -7.9 pts |
| Net margin | 3.2% | 11.6% | -8.4 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumer Products segment | $24.2M | $22.7M | $1.5M | +6% |
| Ingredients segment | $5.4M | $7.6M | −$2.2M | -29% |
| Revenue | $29.8M | $31.1M | −$1.3M | -4% |
| Gross profit | $19.3M | $20.2M | −$912K | -5% |
| Cost of revenue | $10.5M | $10.9M | −$420K | -4% |
| Other income, net | $369K | $552K | −$183K | -33% |
| Operating profit | $700K | $3.2M | −$2.5M | -78% |
| Operating expenses | $18.6M | $17.0M | $1.6M | +9% |
| Pre-tax earnings | $1.1M | $3.7M | −$2.7M | -71% |
| Research & development | $1.5M | $1.6M | −$54K | -3% |
| Sales & marketing | $10.1M | $8.2M | $1.9M | +23% |
| General & admin | $7.0M | $7.3M | −$296K | -4% |
| Net earnings | $963K | $3.6M | −$2.6M | -73% |
| Income tax | $106K | $128K | −$22K | -17% |
| Depreciation & amortization | $291K | $196K | $95K | +48% |
| Share-based compensation | $1.7M | $1.5M | $235K | +16% |
| Working capital & other | $205K | $4.0M | −$3.8M | -95% |
| Operating cash flow | $2.8M | $1.2M | $1.5M | +122% |
Questions
How much did Niagen Bioscience's revenue grow year over year in Q2 2026?
Niagen Bioscience's revenue fell $1.3M (-4%) from $31.1M in Q2 2025 to $29.8M in Q2 2026.
What drove Niagen Bioscience's revenue change in Q2 2026?
Ingredients segment −$2.2M (-29%); Consumer Products segment +$1.5M (+6%).